DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Guggenheim Capital LLC

Guggenheim Capital LLC reduced its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 20.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 115,717 shares of the medical device company's stock after selling 30,236 shares during the period. Guggenheim Capital LLC's holdings in DexCom were worth $8,999,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Versant Capital Management Inc purchased a new stake in DexCom in the fourth quarter valued at $25,000. Private Trust Co. NA grew its holdings in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after acquiring an additional 245 shares during the period. TD Private Client Wealth LLC boosted its position in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares in the last quarter. Larson Financial Group LLC increased its holdings in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC acquired a new position in shares of DexCom in the 4th quarter valued at $38,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Buying and Selling

In other DexCom news, CEO Kevin R. Sayer sold 32,498 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the transaction, the chief executive officer now owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. This trade represents a 8.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares of the company's stock, valued at $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock worth $8,044,178 over the last 90 days. 0.32% of the stock is owned by insiders.

Analysts Set New Price Targets

DXCM has been the topic of several recent analyst reports. Mizuho initiated coverage on shares of DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price on the stock. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and lifted their target price for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Citigroup raised their price target on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Finally, Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, DexCom has a consensus rating of "Moderate Buy" and an average price target of $99.00.

DexCom Stock Up 1.1 %

Shares of DXCM traded up $0.75 during midday trading on Tuesday, hitting $66.86. The company had a trading volume of 498,787 shares, compared to its average volume of 4,207,186. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $139.24. The firm has a market capitalization of $26.22 billion, a P/E ratio of 46.69, a P/E/G ratio of 2.30 and a beta of 1.50. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company's 50-day simple moving average is $74.62 and its 200-day simple moving average is $76.74.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, sell-side analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.